PT  - JOURNAL ARTICLE
AU  - Peluso, Michael J.
AU  - Ryder, Dylan
AU  - Flavell, Robert
AU  - Wang, Yingbing
AU  - Levi, Jelena
AU  - LaFranchi, Brian H.
AU  - Deveau, Tyler-Marie
AU  - Buck, Amanda M.
AU  - Munter, Sadie E.
AU  - Asare, Kofi A.
AU  - Aslam, Maya
AU  - Koch, Wally
AU  - Szabo, Gyula
AU  - Hoh, Rebecca
AU  - Deswal, Monika
AU  - Rodriguez, Antonio
AU  - Buitrago, Melissa
AU  - Tai, Viva
AU  - Shrestha, Uttam
AU  - Lu, Scott
AU  - Goldberg, Sarah A.
AU  - Dalhuisen, Thomas
AU  - Durstenfeld, Matthew S.
AU  - Hsue, Priscilla Y.
AU  - Kelly, J. Daniel
AU  - Kumar, Nitasha
AU  - Martin, Jeffrey N.
AU  - Gambir, Aruna
AU  - Somsouk, Ma
AU  - Seo, Youngho
AU  - Deeks, Steven G.
AU  - Laszik, Zoltan G.
AU  - VanBrocklin, Henry F.
AU  - Henrich, Timothy J.
TI  - Multimodal Molecular Imaging Reveals Tissue-Based T Cell Activation and Viral RNA Persistence for Up to 2 Years Following COVID-19
AID  - 10.1101/2023.07.27.23293177
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.07.27.23293177
4099  - http://medrxiv.org/content/early/2023/07/31/2023.07.27.23293177.short
4100  - http://medrxiv.org/content/early/2023/07/31/2023.07.27.23293177.full
AB  - The etiologic mechanisms of post-acute medical morbidities and unexplained symptoms (Long COVID) following SARS-CoV-2 infection are incompletely understood. There is growing evidence that viral persistence and immune dysregulation may play a major role. We performed whole-body positron emission tomography (PET) imaging in a cohort of 24 participants at time points ranging from 27 to 910 days following acute SARS-CoV-2 infection using a novel radiopharmaceutical agent, [18F]F-AraG, a highly selective tracer that allows for anatomical quantitation of activated T lymphocytes. Tracer uptake in the post-acute COVID group, which included those with and without Long COVID symptoms, was significantly higher compared to pre-pandemic controls in many anatomical regions, including the brain stem, spinal cord, bone marrow, nasopharyngeal and hilar lymphoid tissue, cardiopulmonary tissues, and gut wall. Although T cell activation tended to be higher in participants imaged closer to the time of the acute illness, tracer uptake was increased in participants imaged up to 2.5 years following SARS-CoV-2 infection. We observed that T cell activation in spinal cord and gut wall was associated with the presence of Long COVID symptoms. In addition, tracer uptake in lung tissue was higher in those with persistent pulmonary symptoms. Notably, increased T cell activation in these tissues was also observed in many individuals without Long COVID. Given the high [18F]F-AraG uptake detected in the gut, we obtained colorectal tissue for in situ hybridization SARS-CoV-2 RNA and immunohistochemical studies in a subset of participants with Long COVID symptoms. We identified cellular SARS-CoV-2 RNA in rectosigmoid lamina propria tissue in all these participants, ranging from 158 to 676 days following initial COVID-19 illness, suggesting that tissue viral persistence could be associated with long-term immunological perturbations.Competing Interest StatementMJP reports consulting fees for Gilead Sciences and AstraZeneca, outside the submitted work. TJH reports consulting fees for Roche and Regeneron outside the submitted work.Funding StatementPET-imaging and peripheral blood immune testing was supported by a Merck Investigator Studies Program Grant (to TJH). PET-imaging Gut biopsy collection and testing was supported by grants from the PolyBio Research Foundation (to TJH, HV and MJP). This work was also supported by NIH/National Institute of Allergy and Infectious Diseases grants (3R01AI141003-03S1, R01AI158013, K23AI157875, and K24AI145806); the Zuckerberg San Francisco General Hospital Department of Medicine and Division of HIV, Infectious Diseases, and Global Medicine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of California, San Francisco Institutional Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors